Plasma S100β and NSE levels and progression in multiple sclerosis

Journal of the Neurological Sciences

Volumn 252, Issue 2, 2007, Pages 154-158

  Koch, Marcus ^a   Mostert, Jop ^a   Heersema, Dorothea ^a   Teelken, Albert ^a   De Keyser, Jacques ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Multiple sclerosis; Neuron specific enolase; NSE; Progression; S100 ; Surrogate markers

Indexed keywords

CELL MARKER; NEURON SPECIFIC ENOLASE; PROTEIN S100B; BIOLOGICAL MARKER; ENOLASE; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL FEATURE; CORRELATION ANALYSIS; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RELAPSE; RELAPSING REMITTING MULTIPLE SCLEROSIS; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; BLOOD; CENTRAL NERVOUS SYSTEM DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING;

ADULT; AGED; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE GROWTH FACTORS; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; S100 PROTEINS;

EID: 33845985248     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.11.012     Document Type: Article

References (9)

1. Rovaris M., Confavreux C., Furlan R., Kappos L., Comi G., and Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5 (2006) 343-354
2. Confavreux C., Vukusic S., and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126 (2003) 770-782
3. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
4. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64 (2005) 1144-1151
5. Kremenchutzky M., Rice G.P., Baskerville J., Wingerchuk D.M., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129 (2006) 584-594
6. Lim E.T., Petzold A., Leary S.M., Altmann D.R., Keir G., Thompson E.J., et al. Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. J Negat Results Biomed 3 (2004) 4
7. Cunningham R.T., Morrow J.I., Johnston C.F., and Buchanan K.D. Serum neurone-specific enolase concentrations in patients with neurological disorders. Clin Chim Acta 230 (1994) 117-124
8. Kleine T.O., Benes L., and Zofel P. Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull 61 (2003) 265-279
9. Marangos P.J., and Schmechel D.E. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 10 (1987) 269-295